The impact of PLCO control arm contamination on perceived PSA screening efficacy

Roman Gulati, Alex Tsodikov, Elisabeth M. Wever, Angela B. Mariotto, Eveline A.M. Heijnsdijk, Jeffrey Katcher, Harry J. De Koning, Ruth Etzioni

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Purpose: To quantify the extent to which a clinically significant prostate cancer mortality reduction due to screening could have been masked by control arm screening (contamination) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial. Methods: We used three independently developed models of prostate cancer natural history to conduct a virtual PLCO trial. Simulated participants underwent pre-trial screening based on population patterns. The intervention arm followed observed compliance during the trial then resumed population screening. A contaminated control arm followed observed contamination during the trial then resumed population screening, while an uncontaminated control arm discontinued screening upon entry. We assumed a clinically significant screening benefit, applied population treatments and survival patterns, and calculated mortality rate ratios relative to the contaminated and uncontaminated control arms. Results: The virtual trial reproduced observed incidence, including stage and grade distributions, and control arm mortality after 10 years of complete follow-up. Under the assumed screening benefit, the three models found that contamination increased the mortality rate ratio from 0.68-0.77 to 0.86-0.91, increased the chance of excess mortality in the intervention arm from 0-4 % to 15-28 %, and decreased the power of the trial to detect a mortality difference from 40-70 % to 9-25 %. Conclusions: Our computer simulation models indicate that contamination substantially limited the ability of the PLCO to identify a clinically significant screening benefit. While the trial shows annual screening does not reduce mortality relative to population screening, contamination prevents concluding whether screening reduces mortality relative to no screening.

Original languageEnglish (US)
Pages (from-to)827-835
Number of pages9
JournalCancer Causes and Control
Volume23
Issue number6
DOIs
StatePublished - Jun 1 2012
Externally publishedYes

Fingerprint

Prostate
Lung
Mortality
Population
Computer Simulation
Prostatic Neoplasms
Natural History
Compliance
Incidence

Keywords

  • Computer simulation
  • Early detection of cancer
  • Mortality
  • Prostate-specific antigen
  • Prostatic neoplasms
  • Randomized controlled trial

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Gulati, R., Tsodikov, A., Wever, E. M., Mariotto, A. B., Heijnsdijk, E. A. M., Katcher, J., ... Etzioni, R. (2012). The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes and Control, 23(6), 827-835. https://doi.org/10.1007/s10552-012-9951-8

The impact of PLCO control arm contamination on perceived PSA screening efficacy. / Gulati, Roman; Tsodikov, Alex; Wever, Elisabeth M.; Mariotto, Angela B.; Heijnsdijk, Eveline A.M.; Katcher, Jeffrey; De Koning, Harry J.; Etzioni, Ruth.

In: Cancer Causes and Control, Vol. 23, No. 6, 01.06.2012, p. 827-835.

Research output: Contribution to journalArticle

Gulati, R, Tsodikov, A, Wever, EM, Mariotto, AB, Heijnsdijk, EAM, Katcher, J, De Koning, HJ & Etzioni, R 2012, 'The impact of PLCO control arm contamination on perceived PSA screening efficacy', Cancer Causes and Control, vol. 23, no. 6, pp. 827-835. https://doi.org/10.1007/s10552-012-9951-8
Gulati R, Tsodikov A, Wever EM, Mariotto AB, Heijnsdijk EAM, Katcher J et al. The impact of PLCO control arm contamination on perceived PSA screening efficacy. Cancer Causes and Control. 2012 Jun 1;23(6):827-835. https://doi.org/10.1007/s10552-012-9951-8
Gulati, Roman ; Tsodikov, Alex ; Wever, Elisabeth M. ; Mariotto, Angela B. ; Heijnsdijk, Eveline A.M. ; Katcher, Jeffrey ; De Koning, Harry J. ; Etzioni, Ruth. / The impact of PLCO control arm contamination on perceived PSA screening efficacy. In: Cancer Causes and Control. 2012 ; Vol. 23, No. 6. pp. 827-835.
@article{db396918cddc487e890cad59e9c3df79,
title = "The impact of PLCO control arm contamination on perceived PSA screening efficacy",
abstract = "Purpose: To quantify the extent to which a clinically significant prostate cancer mortality reduction due to screening could have been masked by control arm screening (contamination) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial. Methods: We used three independently developed models of prostate cancer natural history to conduct a virtual PLCO trial. Simulated participants underwent pre-trial screening based on population patterns. The intervention arm followed observed compliance during the trial then resumed population screening. A contaminated control arm followed observed contamination during the trial then resumed population screening, while an uncontaminated control arm discontinued screening upon entry. We assumed a clinically significant screening benefit, applied population treatments and survival patterns, and calculated mortality rate ratios relative to the contaminated and uncontaminated control arms. Results: The virtual trial reproduced observed incidence, including stage and grade distributions, and control arm mortality after 10 years of complete follow-up. Under the assumed screening benefit, the three models found that contamination increased the mortality rate ratio from 0.68-0.77 to 0.86-0.91, increased the chance of excess mortality in the intervention arm from 0-4 {\%} to 15-28 {\%}, and decreased the power of the trial to detect a mortality difference from 40-70 {\%} to 9-25 {\%}. Conclusions: Our computer simulation models indicate that contamination substantially limited the ability of the PLCO to identify a clinically significant screening benefit. While the trial shows annual screening does not reduce mortality relative to population screening, contamination prevents concluding whether screening reduces mortality relative to no screening.",
keywords = "Computer simulation, Early detection of cancer, Mortality, Prostate-specific antigen, Prostatic neoplasms, Randomized controlled trial",
author = "Roman Gulati and Alex Tsodikov and Wever, {Elisabeth M.} and Mariotto, {Angela B.} and Heijnsdijk, {Eveline A.M.} and Jeffrey Katcher and {De Koning}, {Harry J.} and Ruth Etzioni",
year = "2012",
month = "6",
day = "1",
doi = "10.1007/s10552-012-9951-8",
language = "English (US)",
volume = "23",
pages = "827--835",
journal = "Cancer Causes and Control",
issn = "0957-5243",
publisher = "Springer Netherlands",
number = "6",

}

TY - JOUR

T1 - The impact of PLCO control arm contamination on perceived PSA screening efficacy

AU - Gulati, Roman

AU - Tsodikov, Alex

AU - Wever, Elisabeth M.

AU - Mariotto, Angela B.

AU - Heijnsdijk, Eveline A.M.

AU - Katcher, Jeffrey

AU - De Koning, Harry J.

AU - Etzioni, Ruth

PY - 2012/6/1

Y1 - 2012/6/1

N2 - Purpose: To quantify the extent to which a clinically significant prostate cancer mortality reduction due to screening could have been masked by control arm screening (contamination) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial. Methods: We used three independently developed models of prostate cancer natural history to conduct a virtual PLCO trial. Simulated participants underwent pre-trial screening based on population patterns. The intervention arm followed observed compliance during the trial then resumed population screening. A contaminated control arm followed observed contamination during the trial then resumed population screening, while an uncontaminated control arm discontinued screening upon entry. We assumed a clinically significant screening benefit, applied population treatments and survival patterns, and calculated mortality rate ratios relative to the contaminated and uncontaminated control arms. Results: The virtual trial reproduced observed incidence, including stage and grade distributions, and control arm mortality after 10 years of complete follow-up. Under the assumed screening benefit, the three models found that contamination increased the mortality rate ratio from 0.68-0.77 to 0.86-0.91, increased the chance of excess mortality in the intervention arm from 0-4 % to 15-28 %, and decreased the power of the trial to detect a mortality difference from 40-70 % to 9-25 %. Conclusions: Our computer simulation models indicate that contamination substantially limited the ability of the PLCO to identify a clinically significant screening benefit. While the trial shows annual screening does not reduce mortality relative to population screening, contamination prevents concluding whether screening reduces mortality relative to no screening.

AB - Purpose: To quantify the extent to which a clinically significant prostate cancer mortality reduction due to screening could have been masked by control arm screening (contamination) in the Prostate, Lung, Colorectal, and Ovarian (PLCO) trial. Methods: We used three independently developed models of prostate cancer natural history to conduct a virtual PLCO trial. Simulated participants underwent pre-trial screening based on population patterns. The intervention arm followed observed compliance during the trial then resumed population screening. A contaminated control arm followed observed contamination during the trial then resumed population screening, while an uncontaminated control arm discontinued screening upon entry. We assumed a clinically significant screening benefit, applied population treatments and survival patterns, and calculated mortality rate ratios relative to the contaminated and uncontaminated control arms. Results: The virtual trial reproduced observed incidence, including stage and grade distributions, and control arm mortality after 10 years of complete follow-up. Under the assumed screening benefit, the three models found that contamination increased the mortality rate ratio from 0.68-0.77 to 0.86-0.91, increased the chance of excess mortality in the intervention arm from 0-4 % to 15-28 %, and decreased the power of the trial to detect a mortality difference from 40-70 % to 9-25 %. Conclusions: Our computer simulation models indicate that contamination substantially limited the ability of the PLCO to identify a clinically significant screening benefit. While the trial shows annual screening does not reduce mortality relative to population screening, contamination prevents concluding whether screening reduces mortality relative to no screening.

KW - Computer simulation

KW - Early detection of cancer

KW - Mortality

KW - Prostate-specific antigen

KW - Prostatic neoplasms

KW - Randomized controlled trial

UR - http://www.scopus.com/inward/record.url?scp=84862495438&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862495438&partnerID=8YFLogxK

U2 - 10.1007/s10552-012-9951-8

DO - 10.1007/s10552-012-9951-8

M3 - Article

VL - 23

SP - 827

EP - 835

JO - Cancer Causes and Control

JF - Cancer Causes and Control

SN - 0957-5243

IS - 6

ER -